The FDA has added a boxed warning, its most serious designation, to Copaxone and Glatopa due to the risk of anaphylaxis, a rare but serious allergic reaction.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
FDA issues warning on anaphylaxis risk with MS drugs
